London, UK – [Insert Date] – The global Alzheimer’s disease (AD) market is on the cusp of...
Medical Research and Clinical Trials
NORMAN, OK – In a significant stride forward for cancer research, scientists at the University of Oklahoma...
Argenx NV, a prominent biopharmaceutical company, has made the strategic decision to terminate the late-stage Phase III...
Oklahoma City, OK – In a significant leap forward for cancer research, scientists at the University of...
Disappointing Phase III results for ArriVent BioPharma’s lead candidate, firmonertinib, in the treatment of non-small cell lung...
OKLAHOMA CITY, OK – In a significant breakthrough that redefines our understanding of aggressive cancers, new research...
A significant setback for ArriVent BioPharma has sent its stock price into a tailspin, following the disappointing...
NORMAN, OKLAHOMA – In a significant breakthrough that could redefine future cancer treatments, new research from the...
The oncology landscape for non-small cell lung cancer (NSCLC) with specific EGFR mutations has taken a significant...
NORMAN, OK – In a groundbreaking discovery that redefines our understanding of aggressive breast cancer, scientists at...
